Senesco Technologies, Inc. (SNT) Provides Summary of SNS01-T Progress in Phase 1b/2a Trial
12/10/2012 9:53:28 AM
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported today that interim results from the on-going Phase 1b/2a study were presented yesterday by Dr. John Lust, the PI at Mayo Clinic, Rochester, MN at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia. As previously disclosed, cohort 1 was completed in August, 2012 and currently two of the planned three patients in cohort 2 have completed dosing. No drug-related serious adverse events or disease limiting toxicities have been recorded to date.
comments powered by